BLRX BioLineRx Ltd.

Nasdaq biolinerx.com


$ 3.65 $ -0.09 (-2.41 %)    

Tuesday, 21-Oct-2025 15:59:51 EDT
QQQ $ 610.29 $ -0.16 (-0.03 %)
DIA $ 469.10 $ 2.20 (0.47 %)
SPY $ 670.98 $ -0.01 (0 %)
TLT $ 91.99 $ 0.45 (0.49 %)
GLD $ 376.61 $ -25.91 (-6.43 %)
$ 3.65
$ 3.77
$ 3.65 x 30
$ 3.91 x 700
$ 3.64 - $ 3.85
$ 2.30 - $ 22.60
10,179
na
543.27M
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biolinerx-and-hemispherian-establish-jv-to-develop-glix1-oral-small-molecule-targeting-dna-damage-response-in-glioblastoma-and-other-cancers

- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only -- FDA IND clearance rec...

 update-bioline-rx-q2-epads-100-beats-120-estimate-sales-304000k-miss-924000k-estimate

BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(1.00) per share which beat the analyst consensus estimate of $(1.20) by...

 hc-wainwright--co-reiterates-buy-on-bioline-rx-maintains-26-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $26 price target.

 why-is-nano-cap-biolinerx-stock-surging-on-friday

BioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with mot...

 jones-trading-upgrades-bioline-rx-to-buy-announces-12-price-target

Jones Trading analyst Justin Walsh upgrades BioLine Rx (NASDAQ:BLRX) from Hold to Buy and announces $12 price target.

Core News & Articles
Market-Moving News for May 30th
05/30/2025 11:15:32

REGN: -13% | Regeneron shares are trading lower after the company and Sanofi said the AERIFY-1 study met its primary endpoint b...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION